Essential hypertension
Drug research and approvals for essential hypertension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 42 studies of essential hypertension are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 26 authorised medicines for it.
- Recruiting worldwide: 42
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 26
- SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .NCT07940075 · Phase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts Aug 11, 2026
- Blood Pressure Control and Safety of Ex-one or Ex-one Plus in Essential HypertensionNCT07930247 · Not reported · HK inno.N Corporation · starts May 21, 2026
- An Extension Trial of GW 906 in Participants With Essential HypertensionNCT07879755 · Not applicable · Shenzhen Salubris Pharmaceuticals Co., Ltd. · starts Jun 12, 2026
- Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney DamageNCT07876544 · Phase 4 · Shanghai Jiao Tong University School of Medicine · starts Sep 22, 2026
- Effects of Isometric Wall Squat Training on Blood Pressure in Adults With HypertensionNCT07868822 · Not applicable · Korea University Guro Hospital · starts Sep 29, 2026
- Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild HypertensionNCT07803835 · Phase 1 · Shanghai Minwei Biotechnology Co., Ltd · starts Mar 19, 2026
- Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood PressureNCT07778966 · Not applicable · University of Alabama at Birmingham · starts Oct 19, 2026
- Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Adults With Newly Diagnosed HypertensionNCT07728630 · Not reported · Josip Juraj Strossmayer University of Osijek · starts May 1, 2026
- Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Children With Newly Diagnosed HypertensionNCT07728643 · Not reported · Josip Juraj Strossmayer University of Osijek · starts Apr 1, 2026
Approved 1
- SpironolactoneMineralocorticoid receptor antagonist
Phase 3 12 of 27
- AmlodipineVoltage-gated L-type calcium channel blocker
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- Olmesartan medoxomilType-1 angiotensin II receptor antagonist
- FimasartanType-1 angiotensin II receptor antagonist
- ValsartanType-1 angiotensin II receptor antagonist
- Azilsartan medoxomilType-1 angiotensin II receptor antagonist
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- Candesartan cilexetilType-1 angiotensin II receptor antagonist
- LosartanType-1 angiotensin II receptor antagonist
- OlmesartanType-1 angiotensin II receptor antagonist
- AliskirenRenin inhibitor
- EplerenoneMineralocorticoid receptor antagonist
Phase 2 12 of 16
- LercanidipineVoltage-gated L-type calcium channel blocker
- Rostafuroxin
- EnalaprilAngiotensin-converting enzyme inhibitor
- LisinoprilAngiotensin-converting enzyme inhibitor
- AprocitentanEndothelin receptor, ET-A/ET-B antagonist
- AllopurinolXanthine dehydrogenase inhibitor
- TadalafilPhosphodiesterase 5A inhibitor
- NebivololBeta-1 adrenergic receptor antagonist
- SacubitrilNeprilysin inhibitor
- LY2623091Mineralocorticoid receptor antagonist
- BexagliflozinSodium/glucose cotransporter 2 inhibitor
- OsilodrostatCytochrome P450 11B1 inhibitor
Phase 1 or earlier 8
- AtorvastatinHMG-CoA reductase inhibitor
- Butane
- Fimasartan potassium trihydrate
- KetoconazoleCytochrome P450 51 inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- DigoxinSodium/potassium-transporting ATPase inhibitor
- Beraprost
How its trials ended
491 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 103 whose ending is known, 80% met their primary endpoint, 2% missed it and 18% stopped early.
- Completed, result not reported24149%
- Met its primary endpoint8217%
- Status unknown7515%
- Ongoing7215%
- Stopped: other or unclear133%
- Stopped: enrollment or feasibility41%
- Missed its primary endpoint2<1%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
| Mar 22, 2016 | Amlodipine / Valsartan MylanAmlodipine; valsartan · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
| Mar 13, 2013 | Actelsar HCTTelmisartan; hydrochlorothiazide · generic | Actavis Group PTC ehf | EMA ↗ |
| Dec 7, 2011 | EdarbiAzilsartan medoxomil | Takeda Pharma A/S | EMA ↗ |
| Oct 3, 2011 | Telmisartan Teva PharmaTelmisartan · generic | Teva B.V. | EMA ↗ |
| Mar 4, 2011 | IfirmacombiIrbesartan; hydrochlorothiazide · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Oct 7, 2010 | TwynstaTelmisartan; amlodipine | Boehringer Ingelheim International GmbH | EMA ↗ |
| Sep 29, 2010 | Telmisartan ActavisTelmisartan · generic | Actavis Group PTC ehf | EMA ↗ |
| Jun 4, 2010 | ToluraTelmisartan · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Nov 26, 2009 | Irbesartan/Hydrochlorothiazide TevaIrbesartan; hydrochlorothiazide · generic | Teva B.V. | EMA ↗ |
| Nov 3, 2009 | Dafiro HCTAmlodipine besilate; valsartan; hydrochlorothiazide | Novartis Europharm Limited | EMA ↗ |
| Nov 3, 2009 | Copalia HCTAmlodipine; valsartan; hydrochlorothiazide | Novartis Europharm Limited | EMA ↗ |
| Oct 30, 2009 | Irbesartan TevaIrbesartan · generic | Teva B.V. | EMA ↗ |
| Oct 15, 2009 | Exforge HCTAmlodipine besilate; valsartan; hydrochlorothiazide | Novartis Europharm Limited | EMA ↗ |
| Dec 1, 2008 | Ifirmasta (previously Irbesartan Krka)Irbesartan · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Aug 22, 2007 | RasilezAliskiren | Lxo Ireland Designated Activity Company | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA